93PDAnalysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients

ConclusionsThe present study demonstrates that cfDNA and exosomal RNA are a reliable source of AR-variants and their detection predicts resistance to anti-hormonal therapy. The method is sensitive, fast and represents a convenient alternative to other potentially more expensive and less sensitive approaches.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureV. Conteduca: Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Astellas; Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Bayer. U.F.F. De Giorgi: Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Sanofi; Advisory/Consultancy: Astellas; Advisory/Consultancy: Byer; Advisory/Consultancy: BMS; Honoraria (self): Ipsen; Advisory/Consultancy: Janssen; Advisory/Consultancy: Merk; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Sanofi; Travel/Accommodation/Expenses: BMS; Travel/Accommodation/Expenses: Ipsen; Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research